Genetic Variation in PEAR1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes

• Published in: Circulation. Cardiovascular genetics Vol. 6; no. 2; pp. 184 - 192
• Main Authors: Lewis, Joshua P, Ryan, Kathleen, O’Connell, Jeffrey R, Horenstein, Richard B, Damcott, Coleen M, Gibson, Quince, Pollin, Toni I, Mitchell, Braxton D, Beitelshees, Amber L, Pakzy, Ruth, Tanner, Keith, Parsa, Afshin, Tantry, Udaya S, Bliden, Kevin P, Post, Wendy S, Faraday, Nauder, Herzog, William, Gong, Yan, Pepine, Carl J, Johnson, Julie A, Gurbel, Paul A, Shuldiner, Alan R
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.04.2013
• Subjects: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Cohort Studies; Coronary Artery Disease - genetics; Coronary Artery Disease - metabolism; Coronary Artery Disease - prevention & control; Female; Genome-Wide Association Study; Genotype; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Polymorphism, Single Nucleotide; Receptors, Cell Surface - genetics; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology; Ticlopidine - therapeutic use

BACKGROUND—Aspirin or dual antiplatelet therapy with aspirin and clopidogrel is a standard therapy for patients who are at increased risk for cardiovascular events. However, the genetic determinants of variable response to aspirin (alone and in combination with clopidogrel) are not known. METHODS AN...